Ces radiol. 2015, 69(4):229-237 | DOI: 10.55095/CesRadiol2015/034

PET/MRI in the neurodegenerative disorders with cognitive impairmentReview article

Jiří Ferda1, Eva Ferdová1, Jan Baxa1, Vít Matoušek2, Jakub Hort2, Jiří Cerman3
1 Klinika zobrazovacích metod FN, Plzeň
2 Neurologická klinika FN, Plzeň
3 Neurologická klinika FNM, Praha

Review summarizes contemporary approaches in imaging diagnostic of the neurodegenerative diseases presenting with cognitive deficit. Magnetic resonance imaging plays an essential role, it is including the T2 weighted imaging in the planes perpendicular to the longitudinal axes of the temporal lobes, and isotropic T1 weighted images with isotropic resolution. In the assessment of the cortical atrophy, the mediotemporal atrophy score (MTA, Scheltens) and posterior atrophy score (PA, Koedam) are used. Fazekas score assesses the hypoxemic-ischemic influences. When 18F-FDG is used hybrid imaging PET/MRI enables to evaluate the morphological changes, especially within the temporal lobe, with the typical changes of decreased oxidative glycolysis in the temporal lobe ant in the temporoparietal cortex. Targeted method of the Alzheimer disease differentiation is the application of the radiopharmaceutical with the ability to be bind to the amyloid beta. Confirmation of the accumulation such as molecule - florbetaben or flutemetamol to the amyloid beta within the gray matter supports the setting of the highest probability of Alzheimer disease diagnose. In the differential diagnosis of some so-called Parkinson plus syndromes, such as dementia with Lewy bodies, could play the role also the application of 18F-dihydroxyphenylalanine (FDOPA).

Keywords: PET/MRI, neurodegenerative disorders, amyloid beta, FDG, FDOPA
Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: October 15, 2015; Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdová E, Baxa J, Matoušek V, Hort J, Cerman J. PET/MRI in the neurodegenerative disorders with cognitive impairment. Ces radiol. 2015;69(4):229-237. doi: 10.55095/CesRadiol2015/034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey F, Aalten P, Lapuerta P, van de Pol L, van Schijndel R, de Jong R, Barkhof F, Wolz R, Rueckert D, Bocchetta M, Tsolaki M, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, Visser PJ. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiol Aging 2013; 34(8): 2003-2013. Go to original source... Go to PubMed...
    2. Yoshida D, Shimada H, Makizako H, Doi T, Ito K, Kato T, Shimokata H, Washimi Y, Endo H, Suzuki T. The relationship between atrophy of the medial temporal area and daily activities in older adults with mild cognitive impairment. Aging Clin Exp Res 2012; 24(5): 423-429. Go to original source...
    3. Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011; 21(12): 2618-2625. Go to original source... Go to PubMed...
    4. Heurling K, Buckley C, van Laere K, Vandenberghe R, Lubberink M. Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F] flutemetamol. Neuroimage 2015; 121: 184-192. Go to original source... Go to PubMed...
    5. Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, Smith AP, Buckley C. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer' disease: Specific detection of advanced phases of amyloid-β pathology. Alzheimers Dement 2015; 11(8): 975-985. Go to original source... Go to PubMed...
    6. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015; 72(3): 287-294. Go to original source... Go to PubMed...
    7. Ivanoiu A, Dricot L, Gilis N, Grandin C, Lhommel R, Quenon L, Hanseeuw B. Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers. J Alzheimers Dis 2015; 43(3): 835-847. Go to original source... Go to PubMed...
    8. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, Pontecorvo M, Baker SL, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 2014; 41(7): 1398-1407. Go to original source... Go to PubMed...
    9. Thurfjell L, Lötjönen J, Lundqvist R, Koikkalainen J, Soininen H, Waldemar G, Brooks DJ, Vandenberghe R. Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis 2012; 10(1-4): 246-249. Go to original source... Go to PubMed...
    10. Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J Neurol Neurosurg Psychiatry 2015; 86(4): 431-436. Go to original source... Go to PubMed...
    11. Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, Schultze-Mosgau M, Rohde B, Gertz HJ, Reininger C, Sabri O. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med 2013; 54(5): 723-731. Go to original source... Go to PubMed...
    12. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 39(6): 983-989. Go to original source... Go to PubMed...
    13. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52(8): 1210-1217. Go to original source... Go to PubMed...
    14. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10(5): 424-435. Go to original source... Go to PubMed...
    15. Ischi K. PET approaches for diagnosis of demnetia. Am J Neuroradiol 2014; 35(11): 2030-2038. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content